Residual effect of reductions in red blood cell count and haematocrit and haemoglobin levels after 10‐month withdrawal of pioglitazone in patients with Type 2 diabetes

Abstract

In this study, we observed a reversal of body weight gain but no recoveries in red blood cells or haematocrit or haemoglobin levels after stopping pioglitazone for 10 months in patients treated with pioglitazone for 38 months. This finding should prompt a reconsideration of the sustained effect of thiazolidinediones on the haematopoietic system in patients with Type 2 diabetes.

Prevention of type 2 Diabetes Mellitus: Potential of pharmacological agents

“…Pioglitazone has been less fettered by concerns of cardiovascular adverse events compared to rosiglitazone [24,27], but it has been associated with an increased risk of bladder cancer [28], and is no longer prescribed in France or Germany. Long-term treatment with TZDs can decrease bone density [29,30] and hemoglobin levels [31]. The latter may be due to hemodilution with expanded plasma volume, but there also may be a component of suppression of hematopoiesis [31].…”

“…Long-term treatment with TZDs can decrease bone density [29,30] and hemoglobin levels [31]. The latter may be due to hemodilution with expanded plasma volume, but there also may be a component of suppression of hematopoiesis [31]. In spite of these adverse effects, TZDs still may be the appropriate choice for a subset of patients because they promote a marked reduction in insulin resistance.…”

Punicic acid: A potential compound of pomegranate seed oil in Type 2 diabetes mellitus management

“…In terms of effects on HbA1c, most of these antidiabetic drugs have similar effects with the exception of nateglinide and AGIs, which have few effects (Bolen et al, 2007). Moreover, TZDs enhance insulin sensitivity more effectively than others (American Diabetes Association, 2005;Bolen et al, 2007;DeFronzo, et al, 2013;Lin et al, 2014;Xiang et al, 2006). According to the results of studies, TZDs reduce the risk of T2DM by 55-72% (American Diabetes Association, 2005;Investigators, 2006), metformin by 26-31% (Knowler et al, 2002;Ramachandran et al, 2006), and AGIs by 25-41% (Chiasson et al, 2002;Kawamori et al, 2009).…”

“…Indeed, PPARγ performs many beneficial functions in the body, including adipocyte differentiation in adipose tissue, modifying inflammation in the intestine (via interaction with nuclear factor kappa B), increasing fatty acid oxidation, and decreasing triglyceride levels (Dubuquoy et al, 2006;Marion-Letellier, Savoye, & Ghosh, 2016;Paragomi et al, 2014). (Borges et al, 2011;Lin et al, 2014;Loke, Kwok, & Singh, 2011;Loke, Singh, & Furberg, 2009;Piccinni, Motola, Marchesini, & Poluzzi, 2011).…”

Association between serum magnesium and blood count: influence of type 2 diabetes and central obesity

“…Blood cell count is a commonly used and widely available test method and is also associated with type 2 diabetes or obesity to some extent (16)(17)(18)(19) . In addition, in many studies, the use of Mg and serum Mg for disease treatment has been explored based on the relationship between Mg and blood cells (20)(21)(22)(23) .…”